Idera Pharmaceuticals (IDRA) 4.10 $IDRA
Investors look to Lighten Up on Shares of Idera Pharmaceuticals, Shares Down 8.3% (IDRA)
Comtex SmarTrend(R) - Fri Feb 13, 10:08AM CST
Idera Pharmaceuticals (NASDAQ:IDRA) is one of today's worst performing low-priced stocks, down 8.3% to $3.89 on 3.3x average daily volume. Thus far today, Idera Pharmaceuticals has traded 6.5 million shares, vs. average volume of 2.0 million shares per day. The stock has underperformed the Dow (-8.3% to the Dow's 0.3%) and underperformed the S&P 500 (-8.3% to the S&P's 0.2%) during today's trading.
IDRA: 4.10 (-0.14)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 8:15AM CST
CYTK: 7.78 (+1.29), HK: 2.18 (-0.02), CYBR: 52.52 (+6.83), FXEN: 1.99 (+0.10), NBG: 1.61 (+0.18), MBT: 10.36 (+0.62), SDRL: 12.32 (-0.70), MTSN: 4.04 (+0.19), BLDP: 2.66 (-0.26), GDP: 3.58 (+0.29), REXX: 5.08 (+0.13), DNR: 8.66 (+0.39), ZNGA: 2.24 (-0.42), KING: 16.70 (+1.96), SD: 2.09 (+0.14), MX: 7.52 (-7.50), KN: 18.59 (-3.05), GENE: 8.04 (+1.90), VDSI: 27.86 (+2.69), IDRA: 4.10 (-0.14), SFY: 2.91 (+0.26), ARIA: 7.35 (+0.45), FSL: 37.53 (+2.83), PRAN: 1.09 (-0.55), OAS: 16.84 (-0.03)
Idera prices equity offering
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 7:46AM CST
IDRA: 4.10 (-0.14)
Idera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Fri Feb 13, 7:30AM CST
Idera Pharmaceuticals, Inc. (Nasdaq:IDRA) ("Idera" or the "Company"
today announced the pricing of an underwritten public offering of 20,000,000 shares of common stock for a public offering price of $3.75 per share. The Company has granted to the underwriters participating in the offering a 30-day option to purchase up to an additional 3,000,000 shares of common stock. All of the shares in the offering are to be sold by Idera. The offering is expected to close on or about February 19, 2015, subject to customary closing conditions.
IDRA: 4.10 (-0.14)
Idera Pharmaceuticals proposes to issue up to USD75m common stock shares in public offering
M2 - Tue Feb 10, 5:22AM CST
Biopharmaceutical company Idera Pharmaceuticals (NasdaqCM:IDRA) said on Monday that it plans to offer and sell up to USD75m of shares of its common stock in a public offering.
IDRA: 4.10 (-0.14)
Idera Pharma initiates equity offering
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 3:22PM CST
IDRA: 4.10 (-0.14)
Idera Pharmaceuticals Announces Proposed Public Offering of Common Stock
GlobeNewswire - Mon Feb 09, 3:01PM CST
Idera Pharmaceuticals, Inc. (Nasdaq:IDRA) ("Idera" or the "Company" today announced that it intends to offer and sell up to $75,000,000 of shares of its common stock in an underwritten public offering. In connection with this offering, Idera expects to grant the underwriters a 30-day option to purchase additional shares of common stock, equal to up to 15% of the number of shares of common stock sold in the offering. All of the shares in the offering are to be sold by Idera. Idera intends to use the net proceeds from this offering, together with existing cash, cash equivalents and investments, to advance clinical development of certain of its programs. Goldman, Sachs & Co. and J.P. Morgan are acting as joint bookrunning managers for the offering.
IDRA: 4.10 (-0.14), JPM: 59.67 (+0.10)
Capture Growth With Baskets Of Biotechs: LifeSci Advisors' Andrew McDonald
Life Sciences Report - Seeking Alpha - Thu Feb 05, 2:18PM CST
Andrew McDonald believes investors fundamentally underestimate the risk of investing in companies with drugs in development. To address the inherent hazards, McDonald cofounded LifeSci Advisors, which creates exchange-traded funds to limit risk. In...
PCYC: 163.28 (+0.23), IDRA: 4.10 (-0.14), INFI: 15.13 (+0.55), PRTA: 22.89 (+0.13)
Idera Announces Leadership Appointments
GlobeNewswire - Mon Jan 26, 3:30PM CST
Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing immune-modulating and gene silencing therapies for cancer and rare diseases, today announced the appointments of R. Clayton Fletcher as Senior Vice President, Business Development and Strategic Planning, and Jim Baker as Executive Director, Market Development.
IDRA: 4.10 (-0.14)
Cosentyx cleared in Europe
Seeking Alpha - at Seeking Alpha - Mon Jan 19, 4:11PM CST
CANF: 3.85 (+0.05), JNJ: 99.62 (+1.18), IDRA: 4.10 (-0.14), DERM: 16.52 (-0.11), PFE: 34.64 (-0.23), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07), AMGN: 153.48 (+0.30), HSP: 87.35 (unch), CELG: 115.88 (+0.16), NVS: 102.20 (-0.17)
Shares of IDRA Up 93.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Jan 13, 1:32AM CST
SmarTrend identified an Uptrend for Idera Pharmaceuticals (NASDAQ:IDRA) on November 25th, 2014 at $2.69. In approximately 2 months, Idera Pharmaceuticals has returned 93.30% as of today's recent price of $5.19.
IDRA: 4.10 (-0.14)
Idera to Present at the 33rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Fri Jan 09, 12:00PM CST
Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced that Vincent Milano, Idera's Chief Executive Officer will present a corporate update at the 33 Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2015 at 10:30 a.m. Pacific Time / 1:30 p.m. Eastern Time at the Westin St. Francis Hotel in San Francisco. The presentation will be followed by a question and answer session that will begin at 11:00 a.m. Pacific Time / 2:00 p.m. Eastern Time.
IDRA: 4.10 (-0.14), JPM: 59.67 (+0.10)
Idera Gets Orphan Drug Status for its Oncology Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 31, 3:15PM CST
Idera Pharmaceuticals (IDRA) announced that the FDA has granted orphan drug designation to IMO-8400.
JNJ: 99.62 (+1.18), PCYC: 163.28 (+0.23), IDRA: 4.10 (-0.14), AFFX: 11.45 (+0.02)
Idera Pharmaceuticals (IDRA) Is Strong On High Volume Today
at The Street - Tue Dec 30, 9:02AM CST
Trade-Ideas LLC identified Idera Pharmaceuticals (IDRA) as a strong on high relative volume candidate
IDRA: 4.10 (-0.14)
Equities in the 'Sweet Spot', Spot the Potential: Research Reports on Ambev, Liberty Interactive, Idera, Advaxis, and Juno
PR Newswire - Tue Dec 30, 7:50AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Ambev (NYSE: ABEV), Liberty Interactive (NASDAQ: QVCA), Idera (NASDAQ: IDRA) Advaxis (NASDAQ: ADXS), and Juno (NASDAQ: JUNO). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
ADXS: 7.18 (+0.06), IDRA: 4.10 (-0.14), ABEV: 6.37 (-0.07), JUNO: 40.52 (+0.18), QVCB: 28.95 (+0.05), QVCA: 29.47 (+0.42)
Idera Provides Key Updates on Clinical Development of IMO-8400 for Treatment of Waldenstrom's Macroglobulinemia
GlobeNewswire - Tue Dec 30, 7:01AM CST
- FDA grants Orphan Drug Designation for IMO-8400 for the treatment of Waldenstrom's macroglobulinemia
IDRA: 4.10 (-0.14)
Idera Pharmaceuticals (IDRA) Stock Surges After FDA Grants Orphan Designation for Cancer Treatment
at The Street - Mon Dec 29, 3:06PM CST
Shares of Idera Pharmaceuticals (IDRA) surged more than 15% in late afternoon trading on Monday after the FDA granted orphan designation to the company's treatment of Waldenstrom's macroglobulinemia.
IDRA: 4.10 (-0.14)
Idera Pharmaceuticals Going Into 2015
Samreen Agha - at Seeking Alpha - Mon Dec 22, 1:57PM CST
IDRA: 4.10 (-0.14)
Piper Jaffray picks for 2015
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 9:38AM CST
BDX: 143.71 (+0.72), IDRA: 4.10 (-0.14)
Idera Pharmaceuticals (IDRA) Marked As A Dead Cat Bounce Stock
at The Street - Tue Dec 16, 8:45AM CST
Trade-Ideas LLC identified Idera Pharmaceuticals (IDRA) as a "dead cat bounce" (down big yesterday but up big today) candidate
IDRA: 4.10 (-0.14)
Investors look to Lighten Up on Shares of Idera Pharmaceuticals, Shares Down 8.3% (IDRA)
Comtex SmarTrend(R) - Fri Feb 13, 10:08AM CST
Idera Pharmaceuticals (NASDAQ:IDRA) is one of today's worst performing low-priced stocks, down 8.3% to $3.89 on 3.3x average daily volume. Thus far today, Idera Pharmaceuticals has traded 6.5 million shares, vs. average volume of 2.0 million shares per day. The stock has underperformed the Dow (-8.3% to the Dow's 0.3%) and underperformed the S&P 500 (-8.3% to the S&P's 0.2%) during today's trading.
IDRA: 4.10 (-0.14)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 8:15AM CST
CYTK: 7.78 (+1.29), HK: 2.18 (-0.02), CYBR: 52.52 (+6.83), FXEN: 1.99 (+0.10), NBG: 1.61 (+0.18), MBT: 10.36 (+0.62), SDRL: 12.32 (-0.70), MTSN: 4.04 (+0.19), BLDP: 2.66 (-0.26), GDP: 3.58 (+0.29), REXX: 5.08 (+0.13), DNR: 8.66 (+0.39), ZNGA: 2.24 (-0.42), KING: 16.70 (+1.96), SD: 2.09 (+0.14), MX: 7.52 (-7.50), KN: 18.59 (-3.05), GENE: 8.04 (+1.90), VDSI: 27.86 (+2.69), IDRA: 4.10 (-0.14), SFY: 2.91 (+0.26), ARIA: 7.35 (+0.45), FSL: 37.53 (+2.83), PRAN: 1.09 (-0.55), OAS: 16.84 (-0.03)
Idera prices equity offering
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 7:46AM CST
IDRA: 4.10 (-0.14)
Idera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Fri Feb 13, 7:30AM CST
Idera Pharmaceuticals, Inc. (Nasdaq:IDRA) ("Idera" or the "Company"
today announced the pricing of an underwritten public offering of 20,000,000 shares of common stock for a public offering price of $3.75 per share. The Company has granted to the underwriters participating in the offering a 30-day option to purchase up to an additional 3,000,000 shares of common stock. All of the shares in the offering are to be sold by Idera. The offering is expected to close on or about February 19, 2015, subject to customary closing conditions. IDRA: 4.10 (-0.14)
Idera Pharmaceuticals proposes to issue up to USD75m common stock shares in public offering
M2 - Tue Feb 10, 5:22AM CST
Biopharmaceutical company Idera Pharmaceuticals (NasdaqCM:IDRA) said on Monday that it plans to offer and sell up to USD75m of shares of its common stock in a public offering.
IDRA: 4.10 (-0.14)
Idera Pharma initiates equity offering
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 3:22PM CST
IDRA: 4.10 (-0.14)
Idera Pharmaceuticals Announces Proposed Public Offering of Common Stock
GlobeNewswire - Mon Feb 09, 3:01PM CST
Idera Pharmaceuticals, Inc. (Nasdaq:IDRA) ("Idera" or the "Company"
today announced that it intends to offer and sell up to $75,000,000 of shares of its common stock in an underwritten public offering. In connection with this offering, Idera expects to grant the underwriters a 30-day option to purchase additional shares of common stock, equal to up to 15% of the number of shares of common stock sold in the offering. All of the shares in the offering are to be sold by Idera. Idera intends to use the net proceeds from this offering, together with existing cash, cash equivalents and investments, to advance clinical development of certain of its programs. Goldman, Sachs & Co. and J.P. Morgan are acting as joint bookrunning managers for the offering. IDRA: 4.10 (-0.14), JPM: 59.67 (+0.10)
Capture Growth With Baskets Of Biotechs: LifeSci Advisors' Andrew McDonald
Life Sciences Report - Seeking Alpha - Thu Feb 05, 2:18PM CST
Andrew McDonald believes investors fundamentally underestimate the risk of investing in companies with drugs in development. To address the inherent hazards, McDonald cofounded LifeSci Advisors, which creates exchange-traded funds to limit risk. In...
PCYC: 163.28 (+0.23), IDRA: 4.10 (-0.14), INFI: 15.13 (+0.55), PRTA: 22.89 (+0.13)
Idera Announces Leadership Appointments
GlobeNewswire - Mon Jan 26, 3:30PM CST
Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing immune-modulating and gene silencing therapies for cancer and rare diseases, today announced the appointments of R. Clayton Fletcher as Senior Vice President, Business Development and Strategic Planning, and Jim Baker as Executive Director, Market Development.
IDRA: 4.10 (-0.14)
Cosentyx cleared in Europe
Seeking Alpha - at Seeking Alpha - Mon Jan 19, 4:11PM CST
CANF: 3.85 (+0.05), JNJ: 99.62 (+1.18), IDRA: 4.10 (-0.14), DERM: 16.52 (-0.11), PFE: 34.64 (-0.23), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07), AMGN: 153.48 (+0.30), HSP: 87.35 (unch), CELG: 115.88 (+0.16), NVS: 102.20 (-0.17)
Shares of IDRA Up 93.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Jan 13, 1:32AM CST
SmarTrend identified an Uptrend for Idera Pharmaceuticals (NASDAQ:IDRA) on November 25th, 2014 at $2.69. In approximately 2 months, Idera Pharmaceuticals has returned 93.30% as of today's recent price of $5.19.
IDRA: 4.10 (-0.14)
Idera to Present at the 33rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Fri Jan 09, 12:00PM CST
Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced that Vincent Milano, Idera's Chief Executive Officer will present a corporate update at the 33 Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2015 at 10:30 a.m. Pacific Time / 1:30 p.m. Eastern Time at the Westin St. Francis Hotel in San Francisco. The presentation will be followed by a question and answer session that will begin at 11:00 a.m. Pacific Time / 2:00 p.m. Eastern Time.
IDRA: 4.10 (-0.14), JPM: 59.67 (+0.10)
Idera Gets Orphan Drug Status for its Oncology Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 31, 3:15PM CST
Idera Pharmaceuticals (IDRA) announced that the FDA has granted orphan drug designation to IMO-8400.
JNJ: 99.62 (+1.18), PCYC: 163.28 (+0.23), IDRA: 4.10 (-0.14), AFFX: 11.45 (+0.02)
Idera Pharmaceuticals (IDRA) Is Strong On High Volume Today
at The Street - Tue Dec 30, 9:02AM CST
Trade-Ideas LLC identified Idera Pharmaceuticals (IDRA) as a strong on high relative volume candidate
IDRA: 4.10 (-0.14)
Equities in the 'Sweet Spot', Spot the Potential: Research Reports on Ambev, Liberty Interactive, Idera, Advaxis, and Juno
PR Newswire - Tue Dec 30, 7:50AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Ambev (NYSE: ABEV), Liberty Interactive (NASDAQ: QVCA), Idera (NASDAQ: IDRA) Advaxis (NASDAQ: ADXS), and Juno (NASDAQ: JUNO). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
ADXS: 7.18 (+0.06), IDRA: 4.10 (-0.14), ABEV: 6.37 (-0.07), JUNO: 40.52 (+0.18), QVCB: 28.95 (+0.05), QVCA: 29.47 (+0.42)
Idera Provides Key Updates on Clinical Development of IMO-8400 for Treatment of Waldenstrom's Macroglobulinemia
GlobeNewswire - Tue Dec 30, 7:01AM CST
- FDA grants Orphan Drug Designation for IMO-8400 for the treatment of Waldenstrom's macroglobulinemia
IDRA: 4.10 (-0.14)
Idera Pharmaceuticals (IDRA) Stock Surges After FDA Grants Orphan Designation for Cancer Treatment
at The Street - Mon Dec 29, 3:06PM CST
Shares of Idera Pharmaceuticals (IDRA) surged more than 15% in late afternoon trading on Monday after the FDA granted orphan designation to the company's treatment of Waldenstrom's macroglobulinemia.
IDRA: 4.10 (-0.14)
Idera Pharmaceuticals Going Into 2015
Samreen Agha - at Seeking Alpha - Mon Dec 22, 1:57PM CST
IDRA: 4.10 (-0.14)
Piper Jaffray picks for 2015
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 9:38AM CST
BDX: 143.71 (+0.72), IDRA: 4.10 (-0.14)
Idera Pharmaceuticals (IDRA) Marked As A Dead Cat Bounce Stock
at The Street - Tue Dec 16, 8:45AM CST
Trade-Ideas LLC identified Idera Pharmaceuticals (IDRA) as a "dead cat bounce" (down big yesterday but up big today) candidate
IDRA: 4.10 (-0.14)
